Hanafy Doaa M, Leaver David J
School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, NSW 2678, Australia.
ACS Med Chem Lett. 2024 Dec 31;16(3):379-387. doi: 10.1021/acsmedchemlett.4c00568. eCollection 2025 Mar 13.
The World Health Organization (WHO) fungal priority pathogens list (WHO FPPL) published in 2022 highlighted the inequity and research challenges faced by researchers who study pathogenic fungi that afflict humans. Antifungal drugs are the only weapon available to treat infections; however, these drugs are old, are not effective against multidrug-resistant (MDR) fungal strains, and are associated with substantial toxicity in clinical use. This Microperspective summarizes challenges pertaining to antifungal drug discovery in addition to highlighting recent advances and antifungal agents in clinical trials.
世界卫生组织(WHO)2022年发布的真菌重点病原体清单(WHO FPPL)突出了研究感染人类的致病真菌的研究人员所面临的不公平现象和研究挑战。抗真菌药物是治疗感染的唯一可用武器;然而,这些药物年代久远,对多重耐药(MDR)真菌菌株无效,且在临床使用中具有相当大的毒性。本微观视角总结了抗真菌药物研发面临的挑战,同时突出了近期的进展以及正在进行临床试验的抗真菌药物。